Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Andrew P. Aromando purchased 25,500 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The shares were acquired at an average price of C$1.62 per share, for a total transaction of C$41,425.92.
Oncolytics Biotech Trading Down 2.8%
ONC traded down C$0.05 during trading on Friday, hitting C$1.73. 245,934 shares of the stock traded hands, compared to its average volume of 147,357. The firm has a market capitalization of C$133.34 million, a P/E ratio of -4.82 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a 50-day moving average of C$0.92 and a 200 day moving average of C$0.95. Oncolytics Biotech Inc. has a 12-month low of C$0.44 and a 12-month high of C$2.08.
Wall Street Analyst Weigh In
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
View Our Latest Stock Report on Oncolytics Biotech
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access